The global prevalence of chronic kidney disease (CKD) from all causes is increasing with parallel increases in the number of people undergoing renal replacement therapy and increases in costs of care. The pathophysiology of diabetic kidney disease (DKD) is complex and heterogeneous. Clinical trials have shown benefits in renal outcomes with drugs acting on the renin-angiotensin-aldosterone system (RAAS) axis, as well as sodium-glucose cotransporter 2 (SGLT2) inhibitors, and GLP1RA. In this manuscript we review the management of diabetic kidney disease.
de BoerIH, KhuntiK, SaduskyT, . Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int. 2022;102(5):974–989.
2.
RossingP, CaramoriML, ChanJCN, . KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int.2022;102(5):S1–S127.
3.
SugaharaM, PakWLW, TanakaT, TangSCW, NangakuM. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrol Carlton Vic.2021;26(6):491–500.
4.
Barrera-ChimalJ, JaisserF. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. Diabetes Obes Metab. 2020;22 (Suppl 1):16–31.
5.
Diabetic kidney disease: Manifestations, evaluation, and diagnosis - UpToDate [Internet]. [cited November28, 2023]. Available from: https://www.uptodate.com/contents/diabetic-kidney-disease-manifestations-evaluation-and-diagnosis
6.
KligerAS, BrosiusFC. Preserving kidney function instead of replacing it. Clin J Am Soc Nephrol CJASN. 2020;15(1): 129–131.
7.
ChanJC, SoWY, YeungCY, . Effects of structured versus usual care on renal endpoint in type 2 diabetes: the sure study. Diabetes Care. 2009;32(6):977–982.
8.
FriedLF, EmanueleN, ZhangJH, . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med.2013;369(20):1892–1903.
9.
Ontarget Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
10.
PerkovicV, JardineMJ, NealB, . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med.2019;380(24):2295–2306.
11.
HeerspinkHJL, StefánssonBV, Correa-RotterR, . Dapagliflozin in patients with chronic kidney disease. N Engl J Med.2020;383(15):1436–1446.
12.
EMPA-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127.
13.
ShaikhA, RayJ, CampbellKN. Role of finerenone in the treatment of diabetic kidney disease: patient selection and clinical perspectives. Ther Clin Risk Manag. 2022;18:753–760.
14.
BakrisGL, AgarwalR, AnkerSD, . Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med.2020;383(23):2219–2229.
15.
PittB, FilippatosG, AgarwalR, . Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med.2021;385(24):2252–2263.
16.
RossingP, BaeresFM, BakrisG, . The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(9). Available from: https://pubmed.ncbi.nlm.nih.gov/36651820/
17.
Novo Nordisk [Internet]. [cited November28, 2023]. News Details. Available from: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html
18.
YamazakiT, MimuraI, TanakaT, NangakuM. Treatment of diabetic kidney disease: current and future. Diabetes Metab J.2021;45(1):11–26.
